CD Biosynsis offers advanced Sf9 Cells CRISPR-Cas9 Genome Editing Services, providing precise and highly efficient genetic manipulation in this premier insect cell line. Sf9 cells (derived from Spodoptera frugiperda) are the foundational host for the Baculovirus Expression Vector System (BEVS), widely used for producing complex recombinant proteins, viral proteins, and vaccine antigens. Our services leverage the power of CRISPR-Cas9 to induce targeted DNA double-strand breaks (DSBs), enabling highly efficient Homology-Directed Repair (HDR) for precise gene knock-in, and reliable Non-Homologous End Joining (NHEJ) for gene knockout. We provide end-to-end solutions, from rational target design and gRNA optimization to stable genomic integration and multi-gene editing, accelerating the development of superior Sf9 cell lines for enhanced yield, improved product quality (e.g., humanized glycosylation), and robust bioprocessing performance.
Get a QuoteCRISPR-Cas9 editing is essential for optimizing Sf9 cells, which are central to the Baculovirus Expression Vector System (BEVS). Our services focus on maximizing the insect cell host's natural advantages while addressing key limitations, such as the host's non-mammalian glycosylation and the presence of native proteases. By optimizing the delivery of the CRISPR system (RNP or optimized plasmid), we ensure accurate manipulation. This includes inserting pathways for humanized glycosylation into stable genomic loci or knocking out genes for protease deficiency. This capability is vital for complex bioprocessing projects that demand fast, clean, and stable genomic modifications to enhance product integrity and yield.
CRISPR-Cas9 System
Standard editing platform for targeted DNA double-strand breaks (DSBs), optimized for efficient Sf9 cell transformation using RNP or specialized plasmid delivery methods.
HDR Repair Template Design
Design of large DNA donor templates (up to 10kb) with optimized homology arms to maximize the rate of accurate gene insertion (knock-in) at targeted genomic loci via the Sf9 Homology-Directed Repair pathway.
Multiplex gRNA Assembly
Construction of gRNA arrays for the simultaneous targeting of multiple genes (e.g., knocking out all native glycosylation enzymes) to accelerate advanced chassis engineering.
Gene Knockout (KO)
Permanent deletion or disruption of target genes (e.g., native glycoenzymes, proteases) via NHEJ, resulting in enhanced product quality or stability.
Targeted Gene Knock-in
Accurate integration of expression cassettes (e.g., human glycosyltransferases or chaperones) into stable genomic loci for constitutive, stable expression.
Point Mutation & Tagging
Introduction of precise single-nucleotide polymorphisms (SNPs) or fluorescent/affinity tags to endogenous genes for pathway analysis or protein purification (requires HDR).
Humanized Glycoengineering
Multiplex editing to knockout native insect glycosylation genes (e.g., FUT, $\beta$-galactosidase) and knock-in of mammalian counterparts to produce human-compatible N-glycans.
Protease Deficiency Strain
Knockout of host cell protease genes (e.g., cathepsins) to prevent product degradation and ensure high yield of intact, full-length recombinant proteins.
Enhanced Folding Capacity
Editing chaperone (e.g., BiP) and PDI (Protein Disulfide Isomerase) genes to optimize the ER folding environment, maximizing the solubility and activity of complex proteins.
A systematic process for rational design, precise editing, and stable clone isolation.
1. Rational Design & System Preparation
2. Transfection & Editing
3. Clone Isolation & Screening
4. Verification & Stable Cell Line Delivery
Identify target locus (KO or KI site). Design gRNA(s) for high on-target specificity.
Prepare the Cas9 enzyme/gRNA Ribonucleoprotein (RNP) complex or optimized plasmid for delivery.
Design the large DNA repair template (donor DNA) with necessary homology arms and selection markers (if KI).
Deliver the editing components into the Sf9 host cell line via optimized electroporation or lipofection protocols.
Culture cells for repair mechanisms (NHEJ or HDR) to finalize the genomic edit.
Apply antibiotic selection (e.g., Puromycin) or FACS sorting to enrich for edited clones.
Genotype verification via junction PCR and definitive sequencing of the edited locus to confirm clean edit.
Phenotypic validation of the final clone for stable expression and product quality post-infection.
Delivery of the verified Sf9 master cell bank (MCB) and complete documentation.
Targeted Glycoengineering
Expertise in multiplex KO/KI to humanize the insect cell glycosylation pathway, solving a major quality limitation of the BEVS system for therapeutic protein production.
Stable Genomic Integration
CRISPR-mediated knock-in ensures permanent integration of transgenes into defined host cell genomic loci, providing consistent, virus-independent constitutive expression.
Protease Deficiency Chassis
Precise knockout of native protease genes creates a stabilized chassis, significantly reducing product degradation during the high-yield BEVS production process.
High Efficiency Delivery
Optimization for Sf9 cells, often preferring RNP delivery, ensures transient Cas9 activity and high on-target specificity, maximizing editing yield.
1. Why is CRISPR-Cas9 essential for optimizing Sf9 cells?
CRISPR-Cas9 enables precise editing needed to resolve major BEVS limitations: 1) eliminating non-mammalian glycosylation and 2) knocking out native proteases to enhance product quality and stability.
2. What is the role of the HDR pathway in Sf9 cells?
The Homology-Directed Repair (HDR) pathway is utilized for Gene Knock-in (KI), allowing the precise insertion of new DNA fragments, such as the human glycosylation pathway genes, into a chosen genomic location.
3. How do you handle multi-gene editing for glycosylation?
We use multiplex gRNA arrays to simultaneously target multiple native glycosylation genes (KO) and often couple this with stable knock-in (KI) of several human glycosyltransferases in one or two steps to create the humanized chassis.
4. What is the advantage of using RNP (Ribonucleoprotein) delivery?
RNP (Cas9 protein complexed with gRNA) provides transient, fast-acting editing. This minimizes the time the Cas9 is active, significantly reducing the risk of off-target mutations compared to using plasmid or viral delivery methods.
5. How is the final engineered clone verified?
Verification includes junction PCR and definitive sequencing of the edited locus (for KI) or TIDE/Sanger sequencing (for KO) to confirm clean, precise genomic modification, followed by phenotypic testing.
6. Can the engineered trait be expressed without the baculovirus?
Yes. By using CRISPR/HDR for stable genomic knock-in, the engineered trait (e.g., human glycosylation) is constitutively expressed by the Sf9 cell, independent of the baculovirus infection.
7. What input is required to start a project?
We require the specific Sf9 cell line (if non-standard) and the accession number or sequence of the target gene(s) for knockout or the sequence of the expression cassette for knock-in.
8. What is the benefit of enhancing the folding capacity?
By editing genes like BiP or PDI, the Sf9 host can more efficiently fold and process complex recombinant proteins, leading to a higher yield of soluble, functional product rather than aggregated inclusion bodies.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.